Brief: Precision BioSciences Presents New Preclinical Safety Data For PBGENE-HBV Clinical Candidate For Study Of Liver Congress
05/06/2024 12:45
June 5 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES PRESENTS NEW PRECLINICAL SAFETY DATA
FOR
PBGENE-HBV CLINICAL CANDIDATE AT THE EUROPEAN ASSOCIATION FOR
THE STUDY OF THE LIVER CONGRESS
* PRECISION BIOSCIENCES INC: PBGENE-HBV WAS WELL TOLERATED
ACROSS
MULTIPLE ADMINISTRATIONS WITH NO OFF-TARGET EDITING OBSERVED
* PRECISION BIOSCIENCES INC: IND AND/OR CTA ON-TRACK FOR
SUBMISSION IN 2024
Source text for Eikon: ID:nBw5qrKt4a
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing